Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2002

View Archived Issues

Angiogenix demonstrates angiogenic activity in preclinical trials

New data on the tolerability of gimatecan discussed at ESMO 2002

Chemotherapy-induced neuropathy reported to improve with levocarnitine acetyl hydrochloride

Marine-derived cytotoxic agents a highlight of the ESMO 2002 congress

Lack of efficacy of venlafaxine in fibromyalgia reported at ACR meeting

Vitaxin inhibits alphavbeta3 integrin expression in human synovial tissue engrafted in SCID mice

Pharmacopeia researchers design novel FSH modulators

New viral RNA polymerase inhibitors covered by BioCryst patent

Gruenenthal prepares and tests new antibacterial beta-lactam-siderophore conjugates

Novel triptolide prodrugs and their use in cancer and autoimmune diseases

Novartis claims malate salts of antifungal agent

Series of antiangiogenic and vascular-damaging agents under study at AstraZeneca

Guilford submits amendment to Gliadel Wafer sNDA

Semisynthetic ciclosporin derivatives for use in respiratory disorders prepared at Enanta

Ribapharm submits IND for Hepavir B

Enrollment begins in pivotal phase III trials of Atrisone for acne

Elan returns rights to HCV antisense drug to Isis

Isis and Elan extend collaboration in OraSense joint venture to end of year

Potential new antidementia drug from Fujisawa facilitates hippocampal neurotransmission

BSF-4007877 and BSF-4094664: neuroprotective 5-HT1A receptor agonists

Highly potent and selective 5-HT6 antagonist from Lilly is orally bioavailable and enters the brain

INO-1001 protects rats from ischemic stroke via inhibition of PARP

Erbitux clinical development program update

GPI-1485 enters new phase II trial in Parkinson's disease patients

December date set for advisory committee review of Bexxar

Fujisawa presents a potent new antioxidant, FR-210575, with potential in stroke

Myfortic receives first major approval in Switzerland

Orphan drug status granted for P-113D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...